June 16, 2020 10:41 AM EDTUpdated 10:54 AM
News Briefing

Pro­tein degra­da­tion pi­o­neer C4 Ther­a­peu­tics nabs $170M; Barcelona start­up has €30M to go af­ter can­cer metas­tases

John Carroll

Editor & Founder

→ Pro­tein degra­da­tion has been good to C4 Ther­a­peu­tics. The Wa­ter­town, MA-based biotech just raised $170 mil­lion. That in­cludes a $150 mil­lion B round as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times